Cargando…

Istradefylline for OFF Episodes in Parkinson’s Disease: A US Perspective of Common Clinical Scenarios

The effective management of OFF episodes remains an important unmet need for patients with Parkinson’s disease (PD) who develop motor complications with long-term levodopa therapy. Istradefylline is a selective adenosine A(2A) receptor antagonist for the treatment of patients with PD experiencing OF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isaacson, Stuart H, Betté, Sagari, Pahwa, Rajesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329678/ https://www.ncbi.nlm.nih.gov/pubmed/35910426 http://dx.doi.org/10.2147/DNND.S245197

Ejemplares similares

Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
por: Berger, Amnon A., et al.
Publicado: (2020)

Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier?
por: Isaacson, Stuart H., et al.
Publicado: (2022)

Istradefylline Versus Opicapone for “Off” Episodes in Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Singh, Alok, et al.
Publicado: (2021)

Istradefylline: A novel agent in the treatment of “off” episodes associated with levodopa/carbidopa use in Parkinson disease
por: Cummins, Lauren, et al.
Publicado: (2022)

Istradefylline for Restless Legs Syndrome Associated with Parkinson’s Disease
por: Nuermaimaiti, Maierdanjiang, et al.
Publicado: (2018)

The effect of istradefylline for Parkinson’s disease: A meta-analysis
por: Sako, Wataru, et al.
Publicado: (2017)

Adenosine A(2A) receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease
por: Mizuno, Yoshikuni, et al.
Publicado: (2013)

Cervical Dystonia Resolving After the Onset of Parkinson’s Disease
por: Ortiz, Juan Fernando, et al.
Publicado: (2021)

Istradefylline Improves Impaired Smooth Pursuit Eye Movements in Parkinson’s Disease
por: Fujita, Youshi, et al.
Publicado: (2023)

Feasibility of home dose optimization of apomorphine sublingual film in Parkinson’s disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study
por: Kassubek, Jan, et al.
Publicado: (2023)

Adenosine A(2A) Receptor Occupancy by Long‐Term Istradefylline Administration in Parkinson's Disease
por: Ishibashi, Kenji, et al.
Publicado: (2020)

Separation and identification of an impurity from the istradefylline intermediate
por: Xu, Haojie, et al.
Publicado: (2020)

Efficacy of Istradefylline, an Adenosine A(2A) Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials
por: Hauser, Robert A., et al.
Publicado: (2021)

Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?
por: Hauser, Robert A., et al.
Publicado: (2023)

Reversible istradefylline-induced pleurothotonus in a patient with Parkinson's disease: A case report and literature review
por: Yasuda, Yuzuru
Publicado: (2018)

A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
por: Hattori, Nobutaka, et al.
Publicado: (2020)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
por: Bette, Sagari, et al.
Publicado: (2018)

Multiple System Atrophy – Cerebellar Type: Clinical Picture and Treatment of an Often-Overlooked Disorder
por: Ortiz, Juan Fernando, et al.
Publicado: (2020)

Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods
por: Pahwa, Rajesh, et al.
Publicado: (2023)

Expert Consensus on the Use of On‐Demand Treatments for OFF Episodes in Parkinson's Disease: A Modified Delphi Panel
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects
por: Mukai, Mayumi, et al.
Publicado: (2017)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Correction to: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
por: Pahwa, Rajesh, et al.
Publicado: (2023)

Istradefylline effects on tremor dominance (TD) and postural instability and gait difficulty (PIGD)
por: Torres-Yaghi, Yasar, et al.
Publicado: (2023)

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study
por: Agbo, Felix, et al.
Publicado: (2021)

Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson’s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study
por: Hatano, Taku, et al.
Publicado: (2022)

Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
por: Antonini, Angelo, et al.
Publicado: (2022)

Istradefylline Mitigates Age-Related Hearing Loss in C57BL/6J Mice
por: Shin, Min, et al.
Publicado: (2021)

Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson’s Disease
por: Brillman, Salima, et al.
Publicado: (2023)

Effective Management of “OFF” Episodes in Parkinson’s Disease: Emerging Treatment Strategies and Unmet Clinical Needs
por: Masood, Nbaa, et al.
Publicado: (2023)

Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson’s Disease
por: Isaacson, Jonathan R., et al.
Publicado: (2021)

Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects
por: Dewaeles, Edmone, et al.
Publicado: (2022)

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
por: Tanner, Caroline M., et al.
Publicado: (2020)

ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study
por: Hauser, Robert A., et al.
Publicado: (2017)

Design, Synthesis, and Biological Activity Studies of Istradefylline Derivatives Based on Adenine as A(2A) Receptor Antagonists
por: Wang, Yiyun, et al.
Publicado: (2021)

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102
por: Isaacson, Stuart H., et al.
Publicado: (2018)

Patient Preferences for Treating “OFF” Episodes in Parkinson’s Disease: A Discrete Choice Experiment
por: Thach, Andrew, et al.
Publicado: (2021)

Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT(1A) Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_57r6ispd8ethaugptm8iaropse